Bioatla (BCAB) Stock
Clinical biotech developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Bioatla in July 2026.
BioAtla Inc (BCAB) is a clinical-stage biotechnology company focused on developing conditionally active biologic (CAB) therapies, primarily for oncology. The CAB platform aims to activate antibodies selectively in the tumour microenvironment, potentially improving efficacy while reducing systemic side effects. For investors, key considerations include the early-stage nature of the pipeline, reliance on clinical trial results and regulatory milestones, and a small market capitalisation (around $40.5M) which can mean heightened share-price volatility and financing risk. Catalysts that could move the stock include trial readouts, data updates, partnership deals and financing announcements. Conversely, setbacks in studies or the need to raise capital could dilute shareholders and pressure the share price. This profile is educational and not investment advice; clinical outcomes are uncertain and past performance does not predict future returns. Investors should assess their risk tolerance, review company filings, and consider seeking independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioAtla's stock with a target price of $7, indicating potential growth.
Financial Health
BIOATLA INC is generating modest revenue and cash flow, but it may need improvement to thrive.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring BCAB
Oncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
CAB technology focus
The company’s conditionally active biologics aim to work selectively in tumours; potential benefits exist, but clinical proof is required and outcomes can vary.
Binary clinical catalysts
Trial readouts and regulatory updates can drive meaningful share moves; this creates opportunity but also sharp downside risk if results disappoint.
Partnerships & funding
Collaborations or licensing deals could validate the platform and provide funding, while capital raises may dilute existing holders—assess runway carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
